IP Library Granted Patent US 8,034,386
Granted Patent B2
US 8,034,386 · App. 11/663,123 · Granted Oct 11, 2011

Extract from

Assignees: SSI Co., Ltd.; Kyowa Hakko Bio Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,034,386
App. No.
11/663,123
Granted
Oct 11, 2011
Kind
B2
Abstract

A food material capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer. An extract of Agaricus Blazei Murill comprising an ingredient capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer is provided. This ingredient can be a chromatographic main elution fraction of 100 to 2000 molecular weight obtained through the steps of extracting the fruit body of Agaricus Blazei Murill with hot water, dialyzing the obtained extract and subjecting the obtained dialysis external fluid to chromatography. Alternatively, the above ingredient can be a dialysis external fluid obtained through the steps of extracting the fruit body of Agaricus Blazei Murill with hot water, adding ethanol to the obtained extract to thereby obtain precipitates, and dissolving the precipitates in water and dialyzing the resultant solution.

Claims (10)

1. A method for suppressing breast cancer, comprising:

administering a composition to a subject having breast cancer, wherein the composition comprises a therapeutically effective amount of an Agaricus blazei Murill extract, and a pharmaceutically acceptable carrier.

2. A method for suppressing proliferation of terminal breast cancer, comprising:

administering a composition to a subject in need of suppressing proliferation of terminal breast cancer, wherein the composition comprises a therapeutically effective amount of an Agaricus blazei Murill extract, and a pharmaceutically acceptable carrier.

3. The method according to claim 1 , wherein the extract is a chromatographic main elute fraction of 100 to 2000 molecular weight obtained by the steps of extracting a fruit body of Agaricus blazei Murill with hot water, dialyzing the resultant extract, and subjecting the thus obtained dialysis external fluid to chromatography.

4. The method according to claim 1 , wherein the extract is a dialysis external fluid obtained by the steps of extracting a fruit body of Agaricus blazei Murill with hot water, adding ethanol to the resultant extract, thereby obtaining precipitates, dissolving the precipitates in water, and dialyzing the resultant solution.

5. The method according to claim 2 , wherein the extract is a chromatographic main elute fraction of 100 to 2000 molecular weight obtained by the steps of extracting a fruit body of Agaricus blazei Murill with hot water, dialyzing the resultant extract, and subjecting the thus obtained dialysis external fluid to chromatography.

6. The method according to claim 2 , wherein the extract is a dialysis external fluid obtained by the steps of extracting a fruit body of Agaricus blazei Murill with hot water, adding ethanol to the resultant extract, thereby obtaining precipitates, dissolving the precipitates in water, and dialyzing the resultant solution.

7. The method according to claim 1 , wherein the breast cancer is induced by methyl-N-nitrosourea.

8. The method according to claim 2 , wherein the breast cancer is induced by methyl-N-nitrosourea.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2012
From: KYOWA HAKKO BIO CO., LTD.
To: SSI CO., LTD.
Reel/Frame 028716/0500 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2010
From: LEE, INSU
To: SSI CO., LTD.; KYOWA HAKKO BIO CO., LTD.
Reel/Frame 023909/0705 →
Priority Claims (1)
JP 2004-272373 · Sep 17, 2004 · national
Continuity (1)
Related Publication 20080260772A1 · Oct 23, 2008